Overview

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy of MCI-196 in patients with Type 2 Diabetes based on the changes in blood glucose-related parameters and safety after 12 weeks administration in double-blind, placebo-controlled manner. And in addition, the changes in lipid-related parameters are examined.
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Bile Acids and Salts